Inflow of FDI into India's pharma sector swells by 45% in FY23

6 July 2023

The Foreign Direct Investment (FDI) equity inflow into the pharmaceutical industry in India has jumped by 45.4% in the fiscal year ended March 2023, compared to inflow in the previous fiscal year.

FDI crossed $2.05 billion compared to $1.41 billion of the previous fiscal year. This follows on the back of a decline of 5% in foreign equity infusion for the fiscal year 2021-22.

Data from the Commerce and Industry Ministry shows that from April 2000 to March 2023, cumulative FDI inflows were $21.46 billion. This placed the pharmaceutical sector in India in the eighth place among sectors that attract the largest FDI equity inflows. Inflows were led by the services sector with $631.98 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK